{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T13:22:37Z","timestamp":1787750557901,"version":"build-2784847793"},"reference-count":35,"publisher":"Walter de Gruyter GmbH","issue":"4","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_jtim-2026-0078_s_005\">\n                    <jats:title>Background and Objectives<\/jats:title>\n                    <jats:p>Chronic prostatitis is a highly prevalent urological disorder affecting millions of men globally and significantly impairing quality of life. The aim of this study was to evaluate the efficacy and safety of Shulie'an (SLA) capsules in patients with chronic prostatitis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jtim-2026-0078_s_006\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this multicenter, prospective, open-label, self-controlled clinical trial, 100 male patients with clinically confirmed chronic prostatitis were enrolled in China. The participants received oral SLA (two capsules per dose, three times daily) for 28 days. The primary endpoint was the change in the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) total score from baseline to endpoint. Secondary endpoints included NIH-CPSI individual domain scores and disappearance rate of traditional Chinese medicine (TCM) symptoms. Safety assessments involved monitoring and recording all adverse events throughout the study period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jtim-2026-0078_s_007\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After 28 days of treatment, SLA capsules exhibited significant clinical efficacy, with an overall response rate of 91.75%. The mean NIH-CPSI total score reduction was 9.2\u00b15.82 and 15.0\u00b16.79 points on the 14th and 28th day, respectively. Approximately 95.88% of the participants achieved more than 4-point reduction in the NIH-CPSI score from baseline after treating for 28 days. All symptom domains showed statistically significant improvements, with symptoms of pain being the most remarkable (complete resolution rate: 41.57%). Besides, after 28 days of treatment, the total TCM syndrome score of the participants significantly improved, and the treatment was considerably safe with no reported serious adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jtim-2026-0078_s_008\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study demonstrated that SLA capsules are a promising therapeutic option for chronic prostatitis, significantly improving clinical symptoms and quality of life with a favorable safety profile.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/jtim-2026-0078","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T13:00:08Z","timestamp":1787749208000},"page":"620-629","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of Shulie'an capsules in treating chronic prostatitis: A multicenter, prospective, open-label clinical trial"],"prefix":"10.1515","volume":"14","author":[{"given":"Yuzhuo","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Urology, Peking University First Hospital; The Institution of Urology, Peking University; Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center; National Urological Cancer Center , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Urology, Peking University First Hospital; The Institution of Urology, Peking University; Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center; National Urological Cancer Center , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiansheng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Urology, The First Affiliated Hospital of Anhui Medical University , Hefei , Anhui Province , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Andrology and Sexual Medicine, The Second Hospital of Dalian Medical University , Dalian , Liaoning Province , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7182-0100","authenticated-orcid":false,"given":"Ning","family":"Zhang","sequence":"additional","affiliation":[{"name":"International Cancer Institute, Peking University Health Science Center , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6256-2733","authenticated-orcid":false,"given":"Hui","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Urology, Peking University First Hospital; The Institution of Urology, Peking University; Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center; National Urological Cancer Center , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"key":"2026082612595933008_j_jtim-2026-0078_ref_001","doi-asserted-by":"crossref","unstructured":"Healy R, Thorne C, Manjunath A. Chronic prostatitis (chronic pelvic pain syndrome). BMJ 2023;383:e073908.","DOI":"10.1136\/bmj-2023-073908"},{"key":"2026082612595933008_j_jtim-2026-0078_ref_002","doi-asserted-by":"crossref","unstructured":"Schaeffer AJ. Clinical practice. Chronic prostatitis and the chronic pelvic pain syndrome. N Engl J Med 2006;355:1690\u20131698.","DOI":"10.1056\/NEJMcp060423"},{"key":"2026082612595933008_j_jtim-2026-0078_ref_003","doi-asserted-by":"crossref","unstructured":"Sun Y, Liu Y, Liu B, Zhou K, Yue Z, Zhang W, et al. Efficacy of acupuncture for chronic prostatitis\/chronic pelvic pain syndrome: a randomized trial. Ann Intern Med 2021;174:1357\u20131366.","DOI":"10.7326\/M21-1814"},{"key":"2026082612595933008_j_jtim-2026-0078_ref_004","doi-asserted-by":"crossref","unstructured":"Schaeffer AJ. Epidemiology and evaluation of chronic pelvic pain syndrome in men. Int J Antimicrob Agents 2008;31:S108\u2013111.","DOI":"10.1016\/j.ijantimicag.2007.08.027"},{"key":"2026082612595933008_j_jtim-2026-0078_ref_005","doi-asserted-by":"crossref","unstructured":"Gao J, Gao P, Hao Z, Zhou Z, Liu J, Li H, et al. Comparison of National Institutes of Health-chronic prostatitis symptom index with international index of erectile function 5 in men with chronic prostatitis\/chronic pelvic pain syndrome: a large cross-sectional study in China. BioMed Res Int 2015;2015:560239.","DOI":"10.1155\/2015\/560239"},{"key":"2026082612595933008_j_jtim-2026-0078_ref_006","doi-asserted-by":"crossref","unstructured":"Wagenlehner FME, van Till JWO, Magri V, Perletti G, Houbiers JGA, Weidner W, et al. National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) symptom evaluation in multinational cohorts of patients with chronic prostatitis\/chronic pelvic pain syndrome. Eur Urol 2013;63:953\u2013959.","DOI":"10.1016\/j.eururo.2012.10.042"},{"key":"2026082612595933008_j_jtim-2026-0078_ref_007","doi-asserted-by":"crossref","unstructured":"Ismailov RS, Naboka YL, Gudima IA, Ibishev KS, Kogan MI. Chronic prostatitis\/chronic pelvic pain syndrome (CP\/CPPS) 3a is a classic chronic bacterial prostatitis (CBP). Eur Urol 2021;79:S185\u2013187.","DOI":"10.1016\/S0302-2838(21)00520-0"},{"key":"2026082612595933008_j_jtim-2026-0078_ref_008","doi-asserted-by":"crossref","unstructured":"Rees J, Abrahams M, Doble A, Cooper A, Prostatitis Expert Reference Group (PERG). Diagnosis and treatment of chronic bacterial prostatitis and chronic prostatitis\/chronic pelvic pain syndrome: a consensus guideline. BJU Int 2015;116:509\u2013525.","DOI":"10.1111\/bju.13101"},{"key":"2026082612595933008_j_jtim-2026-0078_ref_009","doi-asserted-by":"crossref","unstructured":"Magistro G, Wagenlehner FME, Grabe M, Weidner W, Stief CG, Nickel JC. Contemporary management of chronic prostatitis\/chronic pelvic pain syndrome. Eur Urol 2016;69:286\u2013297.","DOI":"10.1016\/j.eururo.2015.08.061"},{"key":"2026082612595933008_j_jtim-2026-0078_ref_010","doi-asserted-by":"crossref","unstructured":"Nickel JC, Downey J, Clark J, Casey RW, Pommerville PJ, Barkin J, et al. Levofloxacin for chronic prostatitis\/chronic pelvic pain syndrome in men: a randomized placebo-controlled multicenter trial. Urology 2003;62:614\u2013617.","DOI":"10.1016\/S0090-4295(03)00583-1"},{"key":"2026082612595933008_j_jtim-2026-0078_ref_011","doi-asserted-by":"crossref","unstructured":"Cho R, Kim J, Lee K, Jeon JS. 101: initial and long term responses to terazosin according to treatment periods in men with chronic prostatitis\/chronic pelvic pain syndrome. J Urol 2007;177:35.","DOI":"10.1016\/S0022-5347(18)30366-5"},{"key":"2026082612595933008_j_jtim-2026-0078_ref_012","unstructured":"Tian C. [Therapeutic effect of Shule'an capsule combined with Harnal in treating chronic non-bacterial prostatitis.] Chin J Ethnomed Ethnopharm 2013;22:91\u201392."},{"key":"2026082612595933008_j_jtim-2026-0078_ref_013","unstructured":"Yang Y. [Clinical observation of Shule'an capsule combined with Harnal for chronic non-bacterial prostatitis.] Basic Med Forum 2015;19:90\u201391."},{"key":"2026082612595933008_j_jtim-2026-0078_ref_014","unstructured":"Xiang XH. [Clinical efficacy analysis of Shule'an capsule combined with Harnal in chronic non-bacterial prostatitis.] J Math Med 2016;29:240\u2013242."},{"key":"2026082612595933008_j_jtim-2026-0078_ref_015","doi-asserted-by":"crossref","unstructured":"Xie Z, Zhang X, Li B, Wang Q, Hou Z, Jia H, et al. The efficacy of Chinese herbal medicine on anxiety and depression in patients with chronic prostatitis complicated by sexual dysfunction: a systematic review and meta-analysis protocol. Front Psychiatry 2025;16:1632159.","DOI":"10.3389\/fpsyt.2025.1632159"},{"key":"2026082612595933008_j_jtim-2026-0078_ref_016","unstructured":"Duan L, Yang Z, Chen X, Shen H, Zhao G. [Comparative study on the content of isorhamnetin glycosides in Dafabiao from different sources in Yunnan.] J Yunnan Univ Chin Med 2024;47:76\u201379."},{"key":"2026082612595933008_j_jtim-2026-0078_ref_017","unstructured":"Pan X, Zhu J, Han J, Luo Y, Xiao D. Research progress on the pharmacological effects of isorhamnetin. Prog Mod Biomed 2025;25:193\u2013200."},{"key":"2026082612595933008_j_jtim-2026-0078_ref_018","doi-asserted-by":"crossref","unstructured":"Ziqubu K, Dlodla PV, Joubert E, Muller CJC, Louw J, Tiano L, et al. Isoorientin: a dietary flavone with the potential to ameliorate diverse metabolic complications. Pharmacol Res 2020;158:104867.","DOI":"10.1016\/j.phrs.2020.104867"},{"key":"2026082612595933008_j_jtim-2026-0078_ref_019","doi-asserted-by":"crossref","unstructured":"Manuel RS, Vezina CM. Trends in experimental autoimmune prostatitis: insights into pathogenesis, therapeutic strategies, and redefinition. Am J Clin Exp Urol 2024;12:52\u201363.","DOI":"10.62347\/OUJJ3710"},{"key":"2026082612595933008_j_jtim-2026-0078_ref_020","doi-asserted-by":"crossref","unstructured":"Pontari MA, Ruggieri MR. Mechanisms in prostatitis\/chronic pelvic pain syndrome. J Urol 2004;172:839\u2013845.","DOI":"10.1097\/01.ju.0000136002.76898.04"},{"key":"2026082612595933008_j_jtim-2026-0078_ref_021","doi-asserted-by":"crossref","unstructured":"Litwin MS, McNaughton-Collins M, Fowler FJ, Nickel JC, Calhoun EA, Pontari MA, et al. The National Institutes of Health Chronic Prostatitis Symptom Index: development and validation of a new outcome measure. Chronic Prostatitis Collaborative Research Network. J Urol 1999;162:369\u2013375.","DOI":"10.1016\/S0022-5347(05)68562-X"},{"key":"2026082612595933008_j_jtim-2026-0078_ref_022","doi-asserted-by":"crossref","unstructured":"Proper KJ, Litwin MS, Wang Y, Alexander RB, Calhoun E, Nickel JC, et al. Responsiveness of the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI). Qual Life Res 2006;15:299\u2013305.","DOI":"10.1007\/s11136-005-1317-1"},{"key":"2026082612595933008_j_jtim-2026-0078_ref_023","doi-asserted-by":"crossref","unstructured":"Nickel JC, Krieger JN, McNaughton-Collins M, Anderson RU, Pontari M, Shoskes DA, et al. Alfuzosin and symptoms of chronic prostatitis-chronic pelvic pain syndrome. N Engl J Med 2008;359:2663\u20132673.","DOI":"10.1056\/NEJMoa0803240"},{"key":"2026082612595933008_j_jtim-2026-0078_ref_024","unstructured":"Zheng X. Guidelines for clinical research of new Chinese medicines (trial edition). China Medical Science Press; 2002: 168\u2013172."},{"key":"2026082612595933008_j_jtim-2026-0078_ref_025","unstructured":"Chinese Andrology Professional Committee of Chinese Association of Integrative Medicine. [Expert consensus on integrated traditional Chinese and western medicine diagnosis and treatment of chronic prostatitis.] Chin J Integr Trad West Med 2015;35:933\u201340."},{"key":"2026082612595933008_j_jtim-2026-0078_ref_026","doi-asserted-by":"crossref","unstructured":"Tawfik AM, Radwan MH, Abdulmonem M, Abo-Elenen M, Elgamal SA, Aboufarha MO. Tadalafil monotherapy in management of chronic prostatitis\/chronic pelvic pain syndrome: a randomized double-blind placebo controlled clinical trial. World J Urol 2022;40:2505\u20132511.","DOI":"10.1007\/s00345-022-04074-4"},{"key":"2026082612595933008_j_jtim-2026-0078_ref_027","doi-asserted-by":"crossref","unstructured":"Krieger JN, Nyberg L, Nickel JC. NIH consensus definition and classification of prostatitis. JAMA 1999;282:236\u2013237.","DOI":"10.1001\/jama.282.3.236"},{"key":"2026082612595933008_j_jtim-2026-0078_ref_028","doi-asserted-by":"crossref","unstructured":"Clemens JQ, Meenan RT, O'Keeffe Rosetti MC, Kimes T, Calhoun EA. Prevalence of and risk factors for prostatitis: population based assessment using physician assigned diagnoses. J Urol 2007;178:1333\u20131337.","DOI":"10.1016\/j.juro.2007.05.140"},{"key":"2026082612595933008_j_jtim-2026-0078_ref_029","doi-asserted-by":"crossref","unstructured":"Zhang Y, Ma H, Nan T, Li Y, Zheng W, Zhou Z, et al. Comparative efficacy of oral Chinese patent medicine for chronic prostatitis\/chronic pelvic pain syndrome with sexual dysfunction: a bayesian network meta-analysis of randomized controlled trials. Front Pharmacol 2021;12:649470.","DOI":"10.3389\/fphar.2021.649470"},{"key":"2026082612595933008_j_jtim-2026-0078_ref_030","unstructured":"Lanqun L, Haisong L, Jun G, Song S, Jianmin X, Qiang Z, et al. [Clinical investigation on TCM syndrome types of chronic prostatitis.] China J Trad Chin Med Pharm 2011;26:451\u2013454."},{"key":"2026082612595933008_j_jtim-2026-0078_ref_031","unstructured":"Feixiang Y, Jingqing H, Yaqiang Z. [Preliminary study on common clinical TCM syndrome types and symptoms\/signs of chronic prostatitis.] World Chin Med 2013;8:672\u2013677."},{"key":"2026082612595933008_j_jtim-2026-0078_ref_032","unstructured":"Jun G, Chunying Z. Practical diagnosis and treatment of prostate diseases with integrated traditional Chinese and western medicine. People's Medical Publishing House; 2006: 212\u2013213."},{"key":"2026082612595933008_j_jtim-2026-0078_ref_033","doi-asserted-by":"crossref","unstructured":"Zhang Y, Chen Z, Chen L, Dong Q, Yang DH, Zhang Q, et al. Astragali radix (Huangqi): a time-honored nourishing herbal medicine. Chin Med 2024;19:119.","DOI":"10.1186\/s13020-024-00977-z"},{"key":"2026082612595933008_j_jtim-2026-0078_ref_034","unstructured":"Zeng M, Li M, Zhang L, Zhang B, Wu G, Feng W, et al. Different meridian tropism in three Chinese medicines: Tinglizi (Semen Lepidii Apetali), Yiyiren (Semen Coicis), Cheqianzi (Semen plantaginis). J Tradit Chin Med 2019;39:213\u2013220."},{"key":"2026082612595933008_j_jtim-2026-0078_ref_035","unstructured":"Cheng ME, Zhan ZL, Zhang W, Yang HJ, Shen JZ, Peng HS. [Textual research of \u201cHuangbo\u201d in classical prescriptions]. Zhongguo Zhong Yao Za Zhi 2019;44:4768\u20134771."}],"container-title":["Journal of Translational Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jtim-2026-0078\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jtim-2026-0078\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T13:00:17Z","timestamp":1787749217000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jtim-2026-0078\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,1]]},"references-count":35,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,8,26]]},"published-print":{"date-parts":[[2026,8,26]]}},"alternative-id":["10.1515\/jtim-2026-0078"],"URL":"https:\/\/doi.org\/10.1515\/jtim-2026-0078","relation":{},"ISSN":["2224-4018"],"issn-type":[{"value":"2224-4018","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,1]]}}}